LGD-3303

ID: lgd3303

Aliases: LGD3303, LGD-3033

Type: compound

Route/form: oral preclinical SARM context

Status: research

Evidence level: preclinical

Best data tier: non-human experimental

Support scope: non-human/mechanistic, review/regulatory

Source types: preclinical, review

Linked sources: 2

Broad outcomes: Muscle growth / performance / recovery, PEDs / AAS / thermogenics, Safety / regulatory

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• androgen receptor modulator
• nonsteroidal SARM

Optimization domains

• SARM
• bone
• muscle
• doping

Research basis

• Preclinical PK/PD work supports LGD-3303 as an orally available tissue-selective AR modulator.
• Useful contrast with LGD-4033 because forum naming often blurs Ligand SARM codes.
• The available evidence is best used for receptor/tissue-selectivity mapping rather than practical cycle design.

Limits, risks, and missing evidence

• No mature human efficacy package was identified.
• Doping/metabolism literature does not establish performance benefit.
• SARM-class endocrine, lipid/liver, androgen-sensitive tissue, and product-identity concerns remain.

Risk flags

• research compound
• preclinical only
• sarm class risk
• product identity risk
• doping

Linked papers, labels, and reviews

1. Pharmacokinetics and pharmacodynamics of LGD-3303
   preclinical / sciencedirect_lgd3303_pkpd_2009
   Preclinical PK/PD study of LGD-3303 as an orally available nonsteroidal SARM.
2. Selective androgen receptor modulators in preclinical and clinical development
   review / pubmed_sarms_preclinical_clinical_2009
   SARM class review covering multiple preclinical and early clinical programs.